Cosmos Health Inc. (COSM)
USD 0.34
(-6.48%)
USD 0.34
(-6.48%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 53.37 Million USD | 6.02% |
| 2022 | 50.34 Million USD | -10.48% |
| 2021 | 56.23 Million USD | 1.5% |
| 2020 | 55.4 Million USD | 39.65% |
| 2019 | 39.67 Million USD | 6.99% |
| 2018 | 37.08 Million USD | 23.56% |
| 2017 | 30.01 Million USD | 344.28% |
| 2016 | 6.75 Million USD | 1165.53% |
| 2015 | 533.8 Thousand USD | -93.01% |
| 2014 | 7.63 Million USD | 746.55% |
| 2013 | 902.36 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 14.58 Million USD | -7.93% |
| 2024 Q2 | 13.2 Million USD | -9.45% |
| 2023 Q3 | 12.82 Million USD | 3.72% |
| 2023 FY | 53.37 Million USD | 6.02% |
| 2023 Q1 | 12.34 Million USD | 2.48% |
| 2023 Q2 | 12.36 Million USD | 0.11% |
| 2023 Q4 | 15.83 Million USD | 23.52% |
| 2022 Q1 | 13.07 Million USD | -19.2% |
| 2022 Q3 | 12.01 Million USD | -9.03% |
| 2022 Q4 | 12.05 Million USD | 0.29% |
| 2022 FY | 50.34 Million USD | -10.48% |
| 2022 Q2 | 13.2 Million USD | 1.05% |
| 2021 Q2 | 14.84 Million USD | 27.78% |
| 2021 Q3 | 13.59 Million USD | -8.43% |
| 2021 Q4 | 16.17 Million USD | 19.0% |
| 2021 FY | 56.23 Million USD | 1.5% |
| 2021 Q1 | 11.61 Million USD | -28.72% |
| 2020 Q1 | 11.93 Million USD | 1.19% |
| 2020 Q4 | 16.3 Million USD | 13.58% |
| 2020 Q3 | 14.35 Million USD | 11.95% |
| 2020 FY | 55.4 Million USD | 39.65% |
| 2020 Q2 | 12.81 Million USD | 7.43% |
| 2019 Q2 | 8.51 Million USD | -12.08% |
| 2019 Q4 | 11.79 Million USD | 21.76% |
| 2019 FY | 39.67 Million USD | 6.99% |
| 2019 Q1 | 9.68 Million USD | 24.89% |
| 2019 Q3 | 9.68 Million USD | 13.76% |
| 2018 Q2 | 8.85 Million USD | -25.98% |
| 2018 Q3 | 8.5 Million USD | -3.94% |
| 2018 Q4 | 7.75 Million USD | -8.88% |
| 2018 FY | 37.08 Million USD | 23.56% |
| 2018 Q1 | 11.96 Million USD | 16.87% |
| 2017 Q1 | 4.11 Million USD | 26.7% |
| 2017 FY | 30.01 Million USD | 344.28% |
| 2017 Q4 | 10.23 Million USD | 7.24% |
| 2017 Q3 | 9.54 Million USD | 56.19% |
| 2017 Q2 | 6.11 Million USD | 48.51% |
| 2016 Q2 | 955.89 Thousand USD | -15.88% |
| 2016 Q4 | 3.24 Million USD | 129.67% |
| 2016 Q3 | 1.41 Million USD | 47.98% |
| 2016 FY | 6.75 Million USD | 1165.53% |
| 2016 Q1 | 1.13 Million USD | 112.89% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 100.0% |
| 2015 FY | 533.8 Thousand USD | -93.01% |
| 2015 Q4 | 533.8 Thousand USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q2 | 1.23 Million USD | 58.01% |
| 2014 Q1 | 781.05 Thousand USD | -13.44% |
| 2014 Q3 | 5.77 Million USD | 368.25% |
| 2014 Q4 | -155.19 Thousand USD | -102.69% |
| 2014 FY | 7.63 Million USD | 746.55% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | 902.36 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q4 | 902.36 Thousand USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 90.582% |
| Embecta Corp. | 1.12 Billion USD | 95.238% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 89.036% |
| Dynavax Technologies Corporation | 232.28 Million USD | 77.021% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 54.118% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 92.092% |
| PainReform Ltd. | - USD | -Infinity% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -5.523% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -121.547% |
| SCYNEXIS, Inc. | 140.14 Million USD | 61.912% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -2667.797% |
| Journey Medical Corporation | 79.18 Million USD | 32.589% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -121.547% |
| Safety Shot Inc | 202.67 Thousand USD | -26236.84% |
| Alpha Teknova, Inc. | 36.68 Million USD | -45.505% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 88.506% |
| Bright Green Corporation | 401.49 Thousand USD | -13194.663% |
| Procaps Group, S.A. | 409.92 Million USD | 86.979% |
| Theratechnologies Inc. | 81.76 Million USD | 34.718% |
| Harrow Health, Inc. | 130.19 Million USD | 59.002% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -319.135% |
| Biofrontera Inc. | 34.07 Million USD | -56.664% |
| DURECT Corporation | 8.54 Million USD | -524.437% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 91.214% |
| Cronos Group Inc. | 88.84 Million USD | 39.919% |
| OptiNose, Inc. | 70.98 Million USD | 24.808% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 87.944% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -719.522% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 87.677% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -335.781% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -34.952% |
| Radius Health, Inc. | 2.88 Billion USD | 98.148% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -65.209% |
| ProPhase Labs, Inc. | 44.38 Million USD | -20.262% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 94.755% |
| Procaps Group S.A. | 409.92 Million USD | 86.979% |
| Alvotech | 91.43 Million USD | 41.623% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -3999.606% |
| Viatris Inc. | 15.42 Billion USD | 99.654% |
| Rockwell Medical, Inc. | 83.61 Million USD | 36.161% |
| Aytu BioPharma, Inc. | 81 Million USD | 34.104% |
| SIGA Technologies, Inc. | 139.91 Million USD | 61.851% |
| Tilray Brands, Inc. | 788.94 Million USD | 93.234% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 58.384% |
| Shineco, Inc. | 9.8 Million USD | -444.559% |
| PetIQ, Inc. | 1.1 Billion USD | 95.156% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 12 Thousand USD | -444707.283% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 97.171% |
| Alimera Sciences, Inc. | 80.75 Million USD | 33.902% |
| Silver Spike Investment Corp. | 11.72 Million USD | -355.351% |
| Assertio Holdings, Inc. | 152.06 Million USD | 64.9% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -816.752% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -206.464% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -4858.81% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -90.884% |
| Hempacco Co., Inc. | 4.04 Million USD | -1219.369% |
| Talphera, Inc. | 651 Thousand USD | -8099.213% |
| Alvotech | 91.43 Million USD | 41.623% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 83.141% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 95.883% |
| Currenc Group, Inc. | 53.25 Million USD | -0.228% |
| Kamada Ltd. | 144.75 Million USD | 63.127% |
| Indivior PLC | 1.09 Billion USD | 95.116% |
| Evoke Pharma, Inc. | 5.18 Million USD | -930.316% |
| Flora Growth Corp. | 76.07 Million USD | 29.833% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -4858.81% |
| Evolus, Inc. | 202.08 Million USD | 73.587% |
| HUTCHMED (China) Limited | 837.99 Million USD | 93.63% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 91.717% |
| Akanda Corp. | 2.16 Million USD | -2371.092% |